Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Phase 4 Selexipag Study on Right Ventricular Function in Pulmonary Arterial Hypertension
2019-004783-22Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selexipag in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Change in right ventricular stroke volume. Started Jun 2020; status: completed.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2019-004783-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004783-22.